Sanara MedTech (NSDQ:SMTI) announced today that it appointed Zachary B. Fleming as its new CEO, effective Jan. 1, 2022.
Fort Worth, Texas-based Sanara, formerly known as Wound Management Technologies, develops wound and skincare products for the wound care and surgical tissue repair markets.
“I am proud of what our team has accomplished to date for all of our stakeholders, including the patients, doctors, and clinicians who use our products,” Fleming said in a news release. “I am looking forward to the opportunity to lead the Sanara MedTech team, and to continue to work with Ron and the entire Sanara MedTech board to execute our strategy. Together, we will work to expand our surgical product offering, implement Sanara’s comprehensive wound and skin strategy, and fulfill our mission of providing products and technologies that offer a value-based solution while improving outcomes for wound patients.”
Fleming joined the company as its VP of sales in November 2017 and has since received promotions to surgical division president in May 2019, then co-COO in January 2020.
Before joining Sanara, Fleming held sales nad management roles at both Healthpoint Biotherapeutics and Smith+Nephew.
“Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy,” Sanara Executive Chairman Ron Nixon said. “During his time as president of the surgical division, he has overseen double-digit year over year revenue growth of our business and steered the division through the challenges associated with the COVID-19 pandemic.
“The board of directors and I are confident that he will bring the same leadership skills, strategic vision, and industry expertise to his new role as CEO. I look forward to continuing to work closely with him as we execute our comprehensive wound and skin care strategy.”